GRAIL, Inc. (GRAL)
| Market Cap | 2.14B |
| Revenue (ttm) | 147.17M |
| Net Income (ttm) | -408.35M |
| Shares Out | 41.02M |
| EPS (ttm) | -11.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 438,639 |
| Open | 54.32 |
| Previous Close | 55.02 |
| Day's Range | 51.82 - 55.20 |
| 52-Week Range | 29.95 - 118.84 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 68.17 (+30.59%) |
| Earnings Date | May 5, 2026 |
About GRAL
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology... [Read more]
Financial Performance
In 2025, GRAIL's revenue was $147.17 million, an increase of 17.18% compared to the previous year's $125.60 million. Losses were -$408.35 million, -79.85% less than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for GRAL stock is "Buy." The 12-month stock price target is $68.17, which is an increase of 30.59% from the latest price.
News
GRAIL to Announce First Quarter 2026 Financial Results
MENLO PARK, Calif., April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue fin...
GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting
Detailed NHS-Galleri Trial Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation Final PATHFINDER 2 Study Results Will be Presented as a Late-Breaking Abstract in an Oral Prese...
Grail, Epic Plan Galleri Test Integration For 450 Health Systems
GRAIL, Inc. (NASDAQ: GRAL) shares are up during Wednesday's premarket session.
GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide
Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within Their Existing Patient Portal Collaboration With Epic Will Allow Clinicians to Seamlessly Order the G...
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $GRAL--GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm.
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection
Partnership expands access to breakthrough blood-based cancer screening intoSuperpower's comprehensive health check and personalized plans. SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- Superpower, the...
Grail CEO Bob Ragusa to retire, Josh Ofman named successor
Cancer test maker Grail said on Thursday that chief executive Bob Ragusa will retire effective June 1, and the company's president, Josh Ofman, will take over the helm.
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor
MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will r...
Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time Investigation examines whether Grail's forward guidance omitted material headwinds kn...
GRAIL Transcript: TD Cowen 46th Annual Health Care Conference
NHS-Galleri trial data showed strong stage IV cancer reduction and improved detection rates, supporting regulatory and commercial momentum. FDA approval and CMS reimbursement are expected to hinge on clinical utility, with robust evidence from ongoing and completed studies. The self-pay and digital health markets are expanding rapidly.
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif., March 2, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equ...
GRAIL to Present at the TD Cowen 46th Annual Health Care Conference
MENLO PARK, Calif., Feb. 24, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management...
GRAIL Stock Tumbles — National Health Service Galleri Trial To Blame
GRAIL Inc. (NASDAQ: GRAL) shares are down during Monday's premarket session following the release of results from the NHS-Galleri trial, which evaluated the effectiveness of the Galleri test in reduci...
'Holy Grail' Honus Wagner card sells for over $5M as family auctions it from grandfather's collection
A T206 Honus Wagner baseball card in a family collection for 116 years was sold for $5.124 million at auction, becoming the third-most expensive ever for this specific card.
This once-hot cancer-detection company's stock got cut in half after a failed trial
Grail's stock was the Nasdaq's biggest loser Friday, after a key trial of its Galleri early-detection cancer test failed to meet its primary endpoint.
Grail shares plunge after major cancer screening trial misses main goal
Grail shares plunged nearly 50% in premarket trading on Friday after its three-year cancer screening trial failed to meet its main goal, dealing a major blow to the blood test maker.
Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame.
The biotech company said its multi-cancer screening test Galleri did not lead to a “statistically significant reduction” in stage 3 and 4 cancer in a U.K. trial.
Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO--(BUSINESS WIRE)---- $GRAL #Grail--Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Grail, Inc. (NASDAQ: GRAL). The investigation focuses on Grail's executive...
GRAIL Earnings Call Transcript: Q4 2025
Galleri test volumes and revenue grew strongly in 2025, with robust clinical data supporting early cancer detection. Despite not meeting the NHS-Galleri trial's primary endpoint, significant reductions in late-stage diagnoses and strong safety results underpin regulatory and commercial momentum.
GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
Sold More Than 185,000 Galleri® Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over-Year to $136.8 Million Completed Galleri PMA Submission to FDA Shared Topline Results from the NHS-Galleri Tr...
Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate
The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, However A Favorable Trend Was Observed Over Time GRAIL Announces U.S. Sales Force Expansion Based on Stro...
GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results
MENLO PARK, Calif., Feb. 16, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue fina...
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test
FDA Submission Marks a Pivotal Milestone in Advancing Early Cancer Detection, Addressing Unmet Needs in Cancer Screening MENLO PARK, Calif., Jan. 29, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), ...
A Study on Aging Unlocks Holy Grail of Sports Performance
SAN FRANCISCO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Surprisingly, a study of older adults is getting a lot of buzz among peak performance experts in the world of sports. The recent INHANCE neuroimaging s...
GRAIL Transcript: 44th Annual J.P. Morgan Healthcare Conference
Galleri's commercial growth accelerated in 2025, with strong revenue, reduced cash burn, and expanded partnerships. Clinical data show high accuracy and early detection benefits, with major regulatory milestones and broader market access anticipated in 2026.